Beicheng Sun

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4213070/publications.pdf

Version: 2024-02-01

60 papers	3,755 citations	172207 29 h-index	133063 59 g-index
60 all docs	60 docs citations	60 times ranked	6795 citing authors

#	Article	IF	Citations
1	The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. Nature Cancer, 2022, 3, 203-218.	5.7	38
2	Engineered EGCGâ€Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. Advanced Science, 2022, 9, e2105894.	5.6	13
3	IL-33/ST2 signaling in liver transplantation. Cellular and Molecular Immunology, 2021, 18, 761-763.	4.8	6
4	Modulation of IR as a therapeutic target to prevent NASH using NRF from Diceratella elliptica (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor. Phytomedicine, 2021, 80, 153388.	2.3	3
5	Dorsal approach with Glissonian approach for laparoscopic right anatomic liver resections. BMC Gastroenterology, 2021, 21, 138.	0.8	3
6	Conjugated secondary 12Î±-hydroxylated bile acids promote liver fibrogenesis. EBioMedicine, 2021, 66, 103290.	2.7	47
7	The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity, 2021, 54, 1168-1185.e8.	6.6	40
8	IL-22 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1290, 81-88.	0.8	52
9	A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients. Frontiers in Oncology, 2021, 11, 766072.	1.3	2
10	The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. Journal of Hepatology, 2020, 72, 167-182.	1.8	116
11	Long noncoding RNA GMAN promotes hepatocellular carcinoma progression by interacting with eIF4B. Cancer Letters, 2020, 473, 1-12.	3.2	31
12	ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation. Journal of Hepatology, 2020, 72, 976-989.	1.8	36
13	lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway . Cancer Management and Research, 2020, Volume 12, 5395-5408.	0.9	21
14	PTPROt aggravates inflammation by enhancing NF-ÎºB activation in liver macrophages during nonalcoholic steatohepatitis. Theranostics, 2020, 10, 5290-5304.	4.6	22
15	ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6â€mediated Lysine 6â€linked polyubiquitination of ASK1 in hepatocytes. Journal of Cellular and Molecular Medicine, 2020, 24, 7814-7828.	1.6	12
16	TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 731-741.	1.8	193
17	Differences in the prognostic value of tumor size on hepatocellular cancerâ€specific survival stratified by gender in a SEER populationâ€based study. United European Gastroenterology Journal, 2019, 7, 933-941.	1.6	13
18	Guanine nucleotideâ€"binding protein G(i)Î±2 aggravates hepatic ischemiaâ€reperfusion injury in mice by regulating MLK3 signaling. FASEB Journal, 2019, 33, 7049-7060.	0.2	10

#	Article	IF	Citations
19	Laennecâ€™s approach for laparoscopic anatomic hepatectomy based on Laennecâ€™s capsule. BMC Gastroenterology, 2019, 19, 194.	0.8	12
20	Liver Transplantation Using Right Lobe Graft With Focal Nodular Hyperplasia: Report of 2 Cases. Transplantation Proceedings, 2019, 51, 3347-3350.	0.3	0
21	14-3-3Î¶ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating TÂlymphocytes. Cell Death and Disease, 2018, 9, 159.	2.7	96
22	CD97 Promotes Tumor Aggressiveness Through the Traditional G Proteinâ€"Coupled Receptorâ€"Mediated Signaling in Hepatocellular Carcinoma. Hepatology, 2018, 68, 1865-1878.	3.6	55
23	Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. Cell Death and Disease, 2018, 9, 478.	2.7	122
24	Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cellular and Molecular Immunology, 2018, 15, 388-398.	4.8	81
25	The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nature Communications, 2017, 8, 15129.	5.8	271
26	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. Trends in Pharmacological Sciences, 2017, 38, 1041-1051.	4.0	12
27	Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor. Medicine (United States), 2017, 96, e7295.	0.4	5
28	Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget, 2017, 8, 60149-60158.	0.8	110
29	Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2016, 40, 707-715.	1.1	84
30	S100A4 hypomethylation affects epithelial-mesenchymal transition partially induced by LMP2A in nasopharyngeal carcinoma. Molecular Carcinogenesis, 2016, 55, 1467-1476.	1.3	15
31	Obesity and Cancer: The Oil that Feeds the Flame. Cell Metabolism, 2016, 23, 48-62.	7.2	296
32	Inhibition of MTA1 by ERÎ± contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis. Journal of Experimental and Clinical Cancer Research, 2015, 34, 128.	3.5	34
33	PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis. Oncotarget, 2015, 6, 9420-9433.	0.8	27
34	PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma. Journal of Molecular Cell Biology, 2015, 7, 338-350.	1.5	11
35	PTPRO-Associated Hepatic Stellate Cell Activation Plays a Critical Role in Liver Fibrosis. Cellular Physiology and Biochemistry, 2015, 35, 885-898.	1.1	28
36	Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma. Mayo Clinic Proceedings, 2015, 90, 1187-1195.	1.4	30

#	Article	IF	Citations
37	Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database. Oncotarget, 2015, 6, 633-641.	0.8	38
38	Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma. Tumor Biology, 2014, 35, 10267-10273.	0.8	19
39	Survival and Inflammation Promotion Effect of PTPRO in Fulminant Hepatitis Is Associated with NF-Î¹B Activation. Journal of Immunology, 2014, 193, 5161-5170.	0.4	21
40	Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes the Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma via Metastatic Tumor Antigen 1 and Mechanistic Target of Rapamycin Signaling Induction. Journal of Virology, 2014, 88, 11872-11885.	1.5	48
41	The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends in Pharmacological Sciences, 2014, 35, 349-357.	4.0	28
42	PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-Î¹B. Journal of Hepatology, 2014, 60, 306-312.	1.8	30
43	Reply. Hepatology, 2014, 59, 1208-1208.	3.6	5
44	IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer, 2013, 13, 59.	1.1	157
45	IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis through Hepatic Stellate Cell Activation. Journal of Immunology, 2013, 191, 1835-1844.	0.4	256
46	Inflammation and liver tumorigenesis. Frontiers of Medicine, 2013, 7, 242-254.	1.5	78
47	RORÎ³t+IL-17+ neutrophils play a critical role in hepatic ischemiaâ€"reperfusion injury. Journal of Molecular Cell Biology, 2013, 5, 143-146.	1.5	62
48	Successful adult-to-adult liver transplantation of an otherwise discarded partial liver allograft with a cavernous hemangioma: new strategy for expanding liver donor pool. Transplant International, 2013, 26, e79-e80.	0.8	10
49	Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology, 2013, 57, 678-688.	3.6	74
50	TGF-Î² Signaling Is Often Attenuated during Hepatotumorigenesis, but Is Retained for the Malignancy of Hepatocellular Carcinoma Cells. PLoS ONE, 2013, 8, e63436.	1.1	24
51	Obesity, inflammation, and liver cancer. Journal of Hepatology, 2012, 56, 704-713.	1.8	428
52	Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology, 2011, 54, 900-909.	3.6	260
53	miR-22 Promotes HBV-Related Hepatocellular Carcinoma Development in Males. Clinical Cancer Research, 2011, 17, 5593-5603.	3.2	72
54	High expression levels of IKKÎ± and IKKÎ² are necessary for the malignant properties of liver cancer. International Journal of Cancer, 2010, 126, 1263-1274.	2.3	58

#	Article	IF	Citations
55	Hydrodynamics-based transfection of plasmid encoding receptor activator for nuclear factor kappa B-Fc protects against hepatic ischemia/reperfusion injury in mice. Liver Transplantation, 2010, 16, 611-620.	1.3	15
56	The level of oncogene H-Ras correlates with tumorigenicity and malignancy. Cell Cycle, 2008, 7, 934-939.	1.3	5
57	Late onset of severe graftâ€versusâ€host disease following liver transplantation. Transplant Immunology, 2006, 16, 250-253.	0.6	20
58	Immortal ALT+ Human Cells Do Not Require Telomerase Reverse Transcriptase for Malignant Transformation. Cancer Research, 2005, 65, 6512-6515.	0.4	18
59	The Minimal Set of Genetic Alterations Required for Conversion of Primary Human Fibroblasts to Cancer Cells in the Subrenal Capsule Assay. Neoplasia, 2005, 7, 585-593.	2.3	42
60	Progressive Loss of Malignant Behavior in Telomerase-Negative Tumorigenic Adrenocortical Cells and Restoration of Tumorigenicity by Human Telomerase Reverse Transcriptase. Cancer Research, 2004, 64, 6144-6151.	0.4	40